Home
Off-the-shelf
Humanized mice (target-specific)
HSA/hFcRn
Humanized mice (target-specific)

Double-humanized HSA/hFcRn mouse model

Double humanized HSA-hFcRn mouse model as a cutting-edge platform for preclinical development of HSA and FcRn-oriented therapeutics.

Contact Us

Applications of HSA/hFcRn

  • Versatility of therapeutic areas such as oncology, infectious diseases, autoimmune diseases and more
  • Assessment of optimized therapeutics such as Fc-engineered antibodies, HSA fusion or binding proteins and small molecules
  • Compound screening based on extended half-life
  • Assessment of pharmacokinetics and pharmacodynamics (PK/PD) features, including biodistribution and binding affinity
  • Syngeneic model for efficacy studies

‍

Key features of HSA/hFcRn

  • Physiological expression and distribution of HSA and human FcRn, driven by murine endogenous promoter. No murine counterparts expressed
  • Optimized PK features based on physiological affinity of human serum albumin for human FcRn

‍

Clients using HSA/hFcRn

  • Avacta Group
  • Novozymes

Validation

Related resources and publications

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

TME

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

nutrition

pain research

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

pulmonary hypertension (PH)

primary sclerosing cholangitis (PSC)

postpartum depression (PPD)

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Case studies
(
0
)
CommentarIes
(
0
)
Scientific Articles
(
0
)
PosterS
(
0
)
Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

8 min read
-
Jan 2022
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

8 min read
-
Apr 2024
An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

3 min read
-
Nov 2022
HSA/hFcRn, a powerful model for your PK/PD studies

Immuno-oncolology models

6 min read
-
Jul 2020
Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin

JCI Insight

May 2024
An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Acta Biomater

Oct 2022
Highlighted article
read the comment
Enhanced half-life and antitumor activity of Interleukin-15 through genetic fusion of a serum albumin-specific protein binder

Int J Pharmac

Jul 2022
Albumin protects the liver from tumor necrosis factor α-induced immunopathology

FASEB J

May 2021
In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders

Bioconjug Chem

Mar 2021
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Commun Biol

Mar 2021
Generation of a double transgenic humanised neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs

J Control Release

Dec 2015
No results
No results

Discover related products to

HSA/hFcRn

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mouse
HSA
PK/PD
Immunodeficient

HSA/hFcRn-Rag1-KO

This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

Double-humanized HSA/hFcRn mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.